SPONSOR
Zhejiang Cancer Hospital
Total Trials
10
Recruiting
10
Phases
Phase 2, Phase 3, Phase 1, Phase 2
Conditions studied: Breast CancerCardiotoxicity Induced by Drug Therapy for Breast CancerBreast Cancer MetastaticAdjuvant RadiotherapyHepatocellular Carcinoma (HCC)Rituximab, Lenalidomide, Zebutinib ，Mantle Cell LymphomaHER2-positive Gastric CancerHER2-positive Gastroesophageal Junction AdenocarcinomaNasopharyngeal CarcinomaPirtobrutinib
Zhejiang Cancer Hospital is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Breast Cancer, Cardiotoxicity Induced by Drug Therapy for Breast Cancer, Breast Cancer Metastatic, Adjuvant Radiotherapy.
The trial portfolio spans Phase 2, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Zhejiang Cancer Hospital
How many clinical trials has Zhejiang Cancer Hospital sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Zhejiang Cancer Hospital, of which 10 are actively recruiting participants. These trials cover conditions including Breast Cancer, Cardiotoxicity Induced by Drug Therapy for Breast Cancer, Breast Cancer Metastatic. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Zhejiang Cancer Hospital research focus on?
Zhejiang Cancer Hospital clinical trials span Breast Cancer, Cardiotoxicity Induced by Drug Therapy for Breast Cancer, Breast Cancer Metastatic, Adjuvant Radiotherapy, Hepatocellular Carcinoma (HCC), and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Zhejiang Cancer Hospital clinical trial?
To participate in a Zhejiang Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Zhejiang Cancer Hospital trials with current recruitment status updated daily.
Clinical Trials by Zhejiang Cancer Hospital
NCT07014410 Phase 2
Recruiting
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Breast Cancer
NCT06214195 Phase 3
Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
NCT06784921
Recruiting
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
Breast Cancer Metastatic
NCT06272214 Phase 2
Recruiting
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Adjuvant Radiotherapy
NCT06741020 Phase 1, Phase 2
Recruiting
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
NCT05992597 Phase 2
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
NCT06572319 Phase 1, Phase 2
Recruiting
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
HER2-positive Gastric Cancer
NCT05126160
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
NCT07416890 Phase 2
Recruiting
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Pirtobrutinib
NCT06538896 Phase 2
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Triple-negative Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology